Bicara Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2023
Period Ending	Mar '26 Mar 20, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Cap	1,034	948	-	-
Market Cap Growth	27.67%	-	-	-
Enterprise Value	741.16	458.77	0	0
Last Close Price	18.87	17.42	-	-
PE Ratio	-	-4.30	-	-
PB Ratio	2.55	1.93	-	-
P/TBV Ratio	2.55	0.60	-	-
P/FCF Ratio	-	-12.67	-	-
P/OCF Ratio	-	-12.69	-	-
EV/EBITDA Ratio	-	-5.57	-	-
EV/EBIT Ratio	-	-5.57	-	-
EV/FCF Ratio	-	-6.13	-	-
Debt / Equity Ratio	0.00	0.00	0.00	0
Debt / EBITDA Ratio	-0.01	-0.01	-0.02	-
Debt / FCF Ratio	-0.02	-0.01	-0.01	-
Net Debt / Equity Ratio	-0.72	-0.99	1.55	0.04
Net Debt / EBITDA Ratio	2.04	5.94	5.76	0.11
Net Debt / FCF Ratio	2.55	6.54	4.97	0.13
Quick Ratio	13.80	27.22	15.28	0.17
Current Ratio	14.14	27.93	15.32	0.21
Return on Equity (ROE)	-27.17%	-19.14%	-51.67%	219.04%
Return on Assets (ROA)	-30.28%	-22.21%	-33.15%	-561.79%
Return on Invested Capital (ROIC)	-240.92%	1977.41%	244.67%	176.37%
Return on Capital Employed (ROCE)	-31.51%	-23.18%	-39.55%	219.02%
Earnings Yield	-11.81%	-23.25%	-	-
FCF Yield	-10.98%	-7.89%	-	-
Buyback Yield / Dilution	-0.01%	-35.22%	-	-

Updated Nov 10, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q